CompanyINDVNasdaqNorth Chesterfield, VA

Indivior Pharmaceuticals, Inc.

Indivior develops long-acting injectable and sublingual buprenorphine medications for opioid use disorder treatment.

SEC EDGAR ClinicalTrials.gov indivior.com

SCHEDULE 13GSep 30Latest SEC filing

Sep 17Latest story

September 2026

Indivior declares $8.13 per share special dividend tied to Supernus merger closing

Sep 17M&AIndivior Pharmaceuticals, Inc.

Indivior and Reckitt Benckiser move up end date of Suboxone/Subutex supply deal

Sep 15Partnershipbuprenorphine hydrochloride, naloxone hydrochloride Indivior Pharmaceuticals, Inc.

August 2026

Indivior and Supernus agree to merger of equals

Aug 3M&AIndivior Pharmaceuticals, Inc.

Indivior raises 2026 guidance on record SUBLOCADE revenue

Aug 3Financingbuprenorphine Indivior Pharmaceuticals, Inc.

Indivior and Supernus agree to merge, forming Supernus, Inc.

Aug 3PartnershipIndivior Pharmaceuticals, Inc.